RT Journal Article
SR Electronic
T1 <span class="underline">C</span>N-105 in Participants with <span class="underline">A</span>cute Supra<span class="underline">T</span>entorial Intra<span class="underline">C</span>erebral <span class="underline">H</span>emorrhage (CATCH) Trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.13.20211417
DO 10.1101/2020.10.13.20211417
A1 Michael L. James
A1 Jesse Troy
A1 Nathaniel Nowacki
A1 Jordan Komisarow
A1 Christa B. Swisher
A1 Kristi Tucker
A1 Kevin Hatton
A1 Marc A. Babi
A1 Bradford B. Worrall
A1 Charles Andrews
A1 Daniel Woo
A1 Peter G. Kranz
A1 Christopher Lascola
A1 Maureen Maughan
A1 Daniel T. Laskowitz
A1 for the CATCH Investigators
YR 2020
UL http://medrxiv.org/content/early/2020/10/15/2020.10.13.20211417.abstract
AB Background Endogenous apoliloprotein E mediates neuroinflammatory responses and recovery after brain injury. Exogenously administered apolipoprotein E-mimetic peptides can effectively penetrate the brain and down-regulate acute inflammation. CN-105 is a novel apolipoprotein E-mimetic pentapeptide with excellent preclinical evidence as an acute intracerebral hemorrhage (ICH) therapeutic. The CN-105 in participants with Acute supraTentorial intraCerebral Hemorrhage (CATCH) trial is a first-in-disease-state, multi-center, open-label trial evaluating safety and feasability of CN-105 administration in patients with acute primary supratentorial ICH.Methods Eligible patients were age 30-80 years, had confirmed primary supratentorial ICH, and able to intiate CN-105 administration (1.0 mg/kg every 6 hours for 72 hours) within 12 hours of symptom onset. A priori defined safety endpoints, including hematoma volume, pharmacokinetics, and 30-day neurological outcomes were analyzed. For comparisons, CATCH participants were matched 1:1 with a contemporary ICH cohort through random selection. Hematoma volumes determined from computed tomography images on Days 0, 1, 2, and 5 and ordinal modified Rankin Score at 30 days after ICH were compared.Results In 39 participants enrolled across six study sites in the United States, adverse events occurred at expected rate without increase in hematoma expansion or neurological deterioration or significant serum accumulation. CN-105 treatment had an odds ratio (95% confidence interval) of 2.69 (1.31–5.51) for lower 30-day mRS, after adjustment for ICH Score, sex, and race/ethnicity, compared to matched contemporary cohort.Conclusion CN-105 administration represents an excellent translational candidate as an actue ICH therapeutic due to its safety, dosing feasibility, favorable pharmacokinetics, and evidence of improved neurological recovery.Competing Interest StatementDTL is an officer and has equity in Aegis-CN. Duke University has equity and an intellectual property stake in CN-105 and might benefit if proven effective and successful commercially. MLJ serves as Principal Investigator for the CATCH trial and received grant funding for the trial from Aegis-CN. JT received personal fees from Aegis-CN during the conduct of this trial. MM is an officer in Aegis-CN.Clinical TrialNCT03168581Funding StatementThe US Food and Drug Administration provided grant funding for this trial (FDA FD-R-5387; DTL, MM). Aegis-CN provided study drug, CN-105, and funding for this trial.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:CATCH was approved by the central institutional review board Copernicus Group Independent Review Board and by the institutional review board for each participating site. All research was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author upon reasonable request.The data that support the findings of this study are available from the corresponding author upon reasonable request.The data that support the findings of this study are available from the corresponding author upon reasonable request.The data that support the findings of this study are available from the corresponding author upon reasonable request.